Maamulka Cuntada iyo Dawooyinka ayaa u fasaxay repotrectinib (Augtyro, Bristol-Myers Squibb Company) ee degaanka horumaray ama metastatic ROS1-positive non-unug yar kansarka sambabada (NSCLC) Noofambar 15, 2023.
Oggolaanshahan FDA ayaa ah tii ugu horeysay ee lagu koobo bukaanada qaba ROS1-positive NSCLC kuwaas oo hore loogu daaweeyay ROS1 tyrosine kinase inhibitor (TKI), iyo sidoo kale shakhsiyaadka aan hore u helin daawaynta TKI.
Oggolaanshaha waxaa la bixiyay ka dib tijaabada caafimaad ee TRIDENT-1 (NCT03093116), daraasad caalami ah oo ay ku jiraan xarumo badan, oo leh hal gacan, nashqad calaamad furan, iyo kooxo bukaan oo kala duwan oo leh ROS1-positive maxalli ahaan u horumaray ama NSCLC metastatic. Waxtarka waxaa lagu qiimeeyay 71 ROS1 TKI-naïve bukaan kuwaas oo maray ugu badnaan 1 xariiq hore oo kiimiko ku salaysan platinum iyo/ama immunotherapy, iyo 56 bukaan oo helay 1 ROS1 TKI hore oo aan lahayn kiimiko ku salaysan platinum-ka hore ama immunotherapy.
Tallaabooyinka waxtarka leh ee aasaasiga ah waxay ahaayeen heerka jawaabta guud (ORR) iyo muddada jawaabta (DOR) ee ku salaysan RECIST v1.1 sida lagu qiimeeyay dib u eegista dhexe ee dhexdhexaadnimada. Heerka Jawaabta Ujeeddada La Xaqiijiyay (ORR) waxay ahayd 79% (95% CI: 68, 88) ee kooxda bukaanada aan lagu daawayn ROS1 TKI kahor, iyo 38% (95% CI: 25, 52) bukaanada kuwaas oo lagu daawayn ka hor ROS1 inhibitor ah. Muddada dhexdhexaadka ah ee jawaabta waxay ahayd bilaha 34.1 (95% CI: 25.6, aan la qiimeyn karin) iyo 14.8 bilood (95% CI: 7.6, aan la qiimeyn karin) labada kooxood, siday u kala horreeyaan. Indho-indhaynta ayaa lagu sameeyay nabarrada maskaxda ee bukaannada qaba habka dhexe ee neerfayaasha ee la qiyaasi karo, iyo sidoo kale shakhsiyaadka leh isbeddellada iska caabinta ka dib daaweynta tyrosine kinase inhibitor.
Jawaabaha ugu xun, ee ku dhaca in ka badan 20% kiisaska, waxay ahaayeen dawakhaad, dysgeusia, neuropathy peripheral neuropathy, calool-istaagga, dyspnea, ataxia, daal, dhibaatooyinka garashada, iyo daciifnimada murqaha.
Qiyaasta la soo jeediyay ee repotrectinib waa 160 mg oo afka laga qaato hal mar maalintii, cunto la'aan ama la'aan, muddo 14 maalmood ah. Ka dib, qiyaasta waa in la kordhiyaa ilaa 160 mg oo la qaato laba jeer maalintii ilaa cudurku ka sii socdo ama sunta aan loo dulqaadan karin.
Kansarka
Lutetium Lu 177 dotatate waxa ansixisay USFDA bukaanada carruurta 12 sano iyo ka weyn ee GEP-NETS
Lutetium Lu 177 dotatate, oo ah daawayn hor leh, ayaa dhawaan ogolaansho ka heshay Maamulka Cunnada iyo Dawooyinka ee Maraykanka (FDA) ee bukaanada carruurta, taas oo calaamad u ah guul muhiim ah oo ku saabsan kansarka carruurta. Oggolaanshahani waxa uu u taagan yahay iftiin rajo u ah carruurta la dagaallamaysa burooyinka neuroendocrine (NETs), oo ah nooc naadir ah laakiin adag oo kansar ah kaas oo inta badan caddeeya u adkaysiga daaweynta caadiga ah.
Alysha Mendossa
Waxaa laga yaabaa 11, 2024
